PURPOSE: BRCA1-interacting protein 1 (BRIP1; FANCJ/BACH1), which encodes a DNA helicase that interacts with BRCA1, has been suggested to be a low-penetrance breast cancer predisposing gene. We aimed to assess whether BRIP1 mutations contribute to breast cancer susceptibility in our population and, if so, to investigate the effect of such mutation(s) on BRIP1 function. EXPERIMENTAL DESIGN: A series of 49 breast/ovarian cancer families, devoid of a BRCA1/BRCA2 mutation, were screened for BRIP1 mutations. Functional analyses, including coimmunoprecipitation and stability assays, were employed to further characterize a previously unreported variant. RESULTS: Five sequence alterations were identified, of which four had been already described. Herein, we report a novel BRIP1 germ-line mutation identified in a woman with early-onset breast cancer. The mutation consists of a 4-nucleotide deletion (c.2992-2995delAAGA) in BRIP1 exon 20 that causes a shift in the reading frame, disrupts the BRCA1-binding domain of BRIP1, and creates a premature stop codon. Functional analysis of the recombinant mutant protein in transfected cells showed that the truncation interferes with the stability of the protein and with its ability to interact with BRCA1. Loss of the wild-type BRIP1 allele with retention of the mutated one was observed in the patient's breast tumor tissue. CONCLUSIONS: These results, by showing that the newly identified BRIP1 c.2992-2995delAAGA mutation is associated with instability and functional impairment of the encoded protein, provide further evidence of a breast cancer-related role for BRIP1.
PURPOSE:BRCA1-interacting protein 1 (BRIP1; FANCJ/BACH1), which encodes a DNA helicase that interacts with BRCA1, has been suggested to be a low-penetrance breast cancer predisposing gene. We aimed to assess whether BRIP1 mutations contribute to breast cancer susceptibility in our population and, if so, to investigate the effect of such mutation(s) on BRIP1 function. EXPERIMENTAL DESIGN: A series of 49 breast/ovarian cancer families, devoid of a BRCA1/BRCA2 mutation, were screened for BRIP1 mutations. Functional analyses, including coimmunoprecipitation and stability assays, were employed to further characterize a previously unreported variant. RESULTS: Five sequence alterations were identified, of which four had been already described. Herein, we report a novel BRIP1 germ-line mutation identified in awoman with early-onset breast cancer. The mutation consists of a 4-nucleotide deletion (c.2992-2995delAAGA) in BRIP1 exon 20 that causes a shift in the reading frame, disrupts the BRCA1-binding domain of BRIP1, and creates a premature stop codon. Functional analysis of the recombinant mutant protein in transfected cells showed that the truncation interferes with the stability of the protein and with its ability to interact with BRCA1. Loss of the wild-type BRIP1 allele with retention of the mutated one was observed in the patient's breast tumor tissue. CONCLUSIONS: These results, by showing that the newly identified BRIP1c.2992-2995delAAGA mutation is associated with instability and functional impairment of the encoded protein, provide further evidence of a breast cancer-related role for BRIP1.
Authors: Alice J Sigurdson; Michael Hauptmann; Nilanjan Chatterjee; Bruce H Alexander; Michele Morin Doody; Joni L Rutter; Jeffery P Struewing Journal: BMC Cancer Date: 2004-03-12 Impact factor: 4.430
Authors: Joni L Rutter; Amelia M Smith; Michael R Dávila; Alice J Sigurdson; Ruthann M Giusti; Marbin A Pineda; Michele M Doody; Margaret A Tucker; Mark H Greene; Jinghui Zhang; Jeffery P Struewing Journal: Hum Mutat Date: 2003-08 Impact factor: 4.878
Authors: Katri Heikkinen; Katrin Rapakko; Sanna-Maria Karppinen; Hannele Erkko; Sakari Knuutila; Tuija Lundán; Arto Mannermaa; Anne-Lise Børresen-Dale; Ake Borg; Rosa B Barkardottir; John Petrini; Robert Winqvist Journal: Carcinogenesis Date: 2006-02-12 Impact factor: 4.944
Authors: Paolo Aretini; Emma D'Andrea; Barbara Pasini; Alessandra Viel; Renato Mariani Costantini; Laura Cortesi; Enrico Ricevuto; Simona Agata; Roberta Bisegna; Mauro Boiocchi; Maria Adelaide Caligo; Luigi Chieco-Bianchi; Giovanna Cipollini; Rosella Crucianelli; Cristina D'Amico; Massimo Federico; Chiara Ghimenti; Clelia De Giacomi; Arcangela De Nicolo; Lara Della Puppa; Sergio Ferrari; Corrado Ficorella; Davide Iandolo; Siranoush Manoukian; Paolo Marchetti; Fabio Marroni; Chiara Menin; Marco Montagna; Laura Ottini; Valeria Pensotti; Marco Pierotti; Paolo Radice; Manuela Santarosa; Vittorio Silingardi; Daniela Turchetti; Generoso Bevilacqua; Silvano Presciuttini Journal: Breast Cancer Res Treat Date: 2003-09 Impact factor: 4.872
Authors: Niall G Howlett; Toshiyasu Taniguchi; Susan Olson; Barbara Cox; Quinten Waisfisz; Christine De Die-Smulders; Nicole Persky; Markus Grompe; Hans Joenje; Gerard Pals; Hideyuki Ikeda; Edward A Fox; Alan D D'Andrea Journal: Science Date: 2002-06-13 Impact factor: 47.728
Authors: Sharon Cantor; Ronny Drapkin; Fan Zhang; Yafang Lin; Juliana Han; Sushmita Pamidi; David M Livingston Journal: Proc Natl Acad Sci U S A Date: 2004-02-24 Impact factor: 11.205
Authors: Avvaru N Suhasini; Joshua A Sommers; Aaron C Mason; Oleg N Voloshin; R Daniel Camerini-Otero; Marc S Wold; Robert M Brosh Journal: J Biol Chem Date: 2009-05-05 Impact factor: 5.157
Authors: Arcangela De Nicolo; Emilio Parisini; Quan Zhong; Maurizia Dalla Palma; Kathryn A Stoeckert; Susan M Domchek; Katherine L Nathanson; Maria A Caligo; Marc Vidal; Michael E Cusick; Judy E Garber Journal: Cancer Res Date: 2009-08-25 Impact factor: 12.701